You're wrong. Your quoting what they said in the JPMorgan breakout session, which was in January. They updated and modified that a couple of months later, on the 4Q11 conference call a few weeks ago. Good luck on your investment.
"They said they expect a slow, steady revenue ramp and that they have less than a year of cash as of today."
Man, you have a real listening comprehension defect.
He said that they had AT LEAST 15 months worth of cash as of December 31, 2011.
He also said that that figure does not take into account:
Any funds from partnership agreements
And, having ANY partners share expenses of worldwide expansion.
He further stated that ANY of the above new partnership deals would "significantly" extend their cash on hand beyond 15 months.
Take that wax out of your ears!
"Savient's own CEO and CFO said on the last earnings call that Savient will need to sell equity in 2012"
NO HE DID NOT! You need to listen better.
He said that they are looking to sell equity IF the stock price recovers.
He also said that they might not need to sell ANY new shares for the near-term if they take in money from new partnership deals.
Savient's own CEO and CFO said on the last earnings call that Savient will need to sell equity in 2012. Listen to the call. They said they expect a slow, steady revenue ramp and that they have less than a year of cash as of today. They said that dilution is coming even though they are also planning to partner in the EU, which will no doubt include a substantial upfront payment.
You are saying that if the stock doesn't double to $4/share, Savient has a financial plan for survival. What's the basis for that claim? You think you know the CEO and CFO's financial requirement and plans better than they do? If so, then why would you entrust your capital to them? What planet are you on?
I don't want interesting, I want profitable.
Short position stratospheric. Those in the know are betting on dilution, or at least protecting against it.
Thin trading. Try to get out of a reasonably sized position. You'll have your butt handed to you.
No information for retail. I mean zero. Those with access and expert networks will hand you your butt.
Murky, murky, murky. And the record is not encouraging.
Good luck. If you are a little guy, this is not for you, IMO. But my record here is also lamentable.
"Those in the know are betting on dilution, or at least protecting against it"
I TOTALLY disagree. Almost EVERY similar small biotech has a huge short position (i.e., HGSI, DNDN, etc).
And HGSI & DNDN definitely do not need ANY dilution anytime soon.
IMHO we are seeing hedge funds shorting every biotech in sight becuase they don't know which ones will suceed and which ones will fail. They're playing it as a basket.